Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTMAB-16 in Pulmonary Sarcoidosis
NCT07680166Phase 2Not yet recruiting
- Sponsor
- Xentria
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing XTMAB-16 with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT07680166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680166.